导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.35% | 2107/4773 |
| 近一周 | -1.75% | 698/5462 |
| 近一月 | 0.42% | 604/5421 |
| 近一季 | -0.52% | 851/5209 |
| 近半年 | -6.01% | 2992/4920 |
| 近一年 | 0.65% | 2511/4366 |
| 近两年 | 20.67% | 2635/2954 |
| 近三年 | 13.19% | 1677/2253 |
| 成立以来 | 67.29% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.30% 759/4961 |
-10.08% 4041/5312 |
- - |
- - |
| 2025 | 4.72% 3035/4813 |
-2.52% 2902/3635 |
3.92% 913/4076 |
1.94% 3851/4524 |
1.40% 1393/4813 |
| 2024 | 11.98% 1283/3463 |
7.20% 255/2808 |
1.83% 440/3014 |
5.68% 2874/3129 |
-2.92% 2207/3463 |
| 2023 | 6.67% 162/2656 |
5.34% 796/2280 |
2.11% 165/2385 |
3.00% 209/2515 |
-3.71% 770/2655 |
| 2022 | -3.77% 71/2207 |
1.42% 102/1919 |
0.09% 1582/2016 |
-3.79% 42/2113 |
-1.48% 1704/2208 |
| 2021 | 17.07% 247/1822 |
6.22% 96/1255 |
6.87% 714/1330 |
4.43% 351/1466 |
-1.25% 1340/1822 |
| 2020 | - - |
- - |
4.98% 895/1067 |
9.09% 676/1164 |
3.98% 879/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 富国中证红利指数增强C VS. 长安沪深300非周期A(740101) |